SCHEMBL5575462

SCHEMBL5575462

NC(=O)C=C[C@](O)(C=O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.35

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.33
SLCO1B1 Q9Y6L6 1/20 0.33
PDE4A P27815 1/20 0.32
LMNA P02545 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27870207 0.80 LMNA (0.43) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL28168488 0.73 USP2 (0.37) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL28259629 0.70 USP2 (0.35) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL1170713 0.70 LMNA (0.40) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL28778146 0.70 LMNA (0.40) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL23705188 0.70 LMNA (0.40) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL1111426 0.70 LMNA (0.40) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL2635057 0.70 LMNA (0.40) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL3172348 0.70 LMNA (0.40) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL6231892 0.69 LMNA (0.36) USP2SLCO1B1PDE4ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884842-B2 Molecular compounds having complementary surfaces to targets ALNIS BIOSCIENCES, INC. (US) 2005-04-26 US claimed
US-20070275046-A1 Noval Surfactants and Applications Thereof TS PHARMA (FR) 2007-11-29 US disclosed
EP-1708993-A2 NOVEL SURFACTANTS AND APPLICATIONS THEREOF TS Pharma (FR) 2006-10-11 EP disclosed
US-20050129769-A1 Polymeric articles for carrying therapeutic agents ALNIS BIOSCIENCES, INC. 2005-06-16 US disclosed
EP-1531868-A2 THERAPEUTIC AGENT-CONTAINING POLYMERIC NANOARTICLES Alnis Biosciences, Inc. (US) 2005-05-25 EP disclosed
WO-2005040105-A2 NOVEL SURFACTANTS AND APPLICATIONS THEREOF TS PHARMA (FR) 2005-05-06 WO disclosed
WO-2005027873-A2 THERAPEUTIC AMINOGLYCOSIDE-CONTAINING HYDROGEL NANOPARTICLES ALNIS BIOSCIENCES, INC. (US) 2005-03-31 WO disclosed
US-20040126900-A1 High affinity peptide- containing nanoparticles ALNIS BIOSCIENCES INC. 2004-07-01 US disclosed
US-20040058006-A1 High affinity nanoparticles ALNIS BIOSCIENCES, INC. 2004-03-25 US disclosed
WO-2003101425-A2 THERAPEUTIC AGENT-CONTAINING POLYMERIC NANOARTICLES ALNIS BIOSCIENCES, INC. (US) 2003-12-11 WO disclosed
EP-1276507-A2 HIGH AFFINITY PEPTIDE-CONTAINING NANOPARTICLES Alnis Biosciences, Inc. (US) 2003-01-22 EP disclosed
WO-2001078786-A2 HIGH AFFINITY PEPTIDE-CONTAINING NANOPARTICLES ALNIS BIOSCIENCES, INC. (US) 2001-10-25 WO disclosed
US-6217901-B1 POLYMERIZING POLYMER AND LIPOSOMES ALNIS, LLC 2001-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050129769-A1 Polymeric articles for carrying therapeutic agents CD44, EPCAM, CLTB USP2 2442/4885SLCO1B1 1266/4885PDE4A 3549/4885
US-20040126900-A1 High affinity peptide- containing nanoparticles LNPEP, IAPP, ACP1 USP2 1071/4885SLCO1B1 3671/4885PDE4A 4437/4885
US-20070275046-A1 Noval Surfactants and Applications Thereof SGMS1, SGMS2, ANXA6 USP2 2445/4885SLCO1B1 1170/4885PDE4A 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.